Autonomix receives US patent for nerve-sensing medical technology

THE WOODLANDS, TX - Autonomix Medical, Inc. (NASDAQ:AMIX), a medical technology company with a current market capitalization of $3.5 million and strong liquidity position evidenced by a current ratio of 5.63, has been granted U.S. Patent No. 12,279,889 B2 for systems and methods related to neurological evaluation and modification, the company announced Friday. According to InvestingPro data, the company maintains more cash than debt on its balance sheet, though it’s currently experiencing rapid cash burn.

The patent covers advanced systems for locating, monitoring, and mapping electrophysiological signals before, during, and after neuromodulation or denervation procedures. It specifically includes tools designed to access small vessels and navigate to target areas to treat cancerous tumors and associated pain. This development comes as the company’s stock has experienced significant volatility, with a year-to-date decline of nearly 67% according to InvestingPro data.

According to the company’s press release, the patented technology is designed to treat conditions influenced by sympathetic nerve activity, including hypertension, chronic pain syndromes, cardiac conditions, and metabolic and neurological disorders.

Brad Hauser, CEO of Autonomix, stated that the patent "represents a significant step forward in our mission to improve patient outcomes by delivering more effective, less invasive treatments for conditions involving the nervous system."

The patent describes technology including sensors integrated into microneedles for deep tissue access, multiband optical sensors, microfingers for tissue contact, and control systems that automatically adjust treatment based on feedback signals.

Autonomix’s platform utilizes a catheter-based microchip sensing array that the company claims may detect neural signals with greater sensitivity than current technologies. The system combines sensing capabilities with radiofrequency ablation technology to target specific nerves.

The company expects to submit an Investigational Device Exemption and begin U.S. clinical trials in 2025 to support commercialization of its Sensing and RF Ablation System as a treatment for pancreatic cancer pain.

The technology remains investigational and has not yet received marketing clearance in the United States.

In other recent news, Autonomix Medical, Inc. announced plans to expand its clinical trial program for cancer pain treatment. The company is set to begin the second phase of its proof-of-concept trial in the second quarter of 2025, following promising results from the initial phase that showed significant pain reduction and decreased opioid use among pancreatic cancer patients. This expansion aims to include other visceral cancers, potentially doubling the addressable market. Autonomix has also secured a new European patent for its nerve technology, enhancing its global patent portfolio. The patent covers systems for regulating organ and tumor growth, which may have applications in treating conditions such as chronic prostatitis and erectile dysfunction. The company is preparing to submit an Investigational Device Exemption to start U.S. clinical trials in 2025. Autonomix’s investigational technology remains in development and has not yet received marketing clearance in the United States. Investors are advised to consider the risks and uncertainties associated with these forward-looking statements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.